GEN3 小时
FDA Accepts for Review Precigen RRP Gene Therapy Candidate
PRGN-2012—which Precigen has begun to call by its generic name of zopapogene imadenovec—is a gene therapy designed to elicit immune responses directed against cells infected with human papillomavirus ...
precisionmedicineonline5 小时
FDA Grants Priority Review to Precigen's Recurrent Respiratory Papillomatosis Gene Therapy
If approved, PRGN-2012 would be the first treatment allowed by the FDA for the rare and chronic disease caused by HPV 6 and HPV 11.
Precigen Gets FDA Priority Review of Recurrent Respiratory Papillomatosis Treatment
Precigen on Tuesday said a green light would make PRGN-2012 the only FDA-approved therapeutic for the treatment of adults with the disorder, which is a lifelong neoplastic disease of the upper and ...
Precigen’s BLA for PRGN-2012 in papillomatosis granted priority review by FDA
Precigen (PGEN) announced the FDA has accepted the company’s biologics license application, or BLA, for PRGN-2012, an investigational ...
震撼！癌症疫苗界“神仙打架”，攻克胰腺癌、胆道癌、胃癌、食管 ...
EVX-01是一种基于肽的个性化癌症疫苗，旨在用于多种晚期实体癌的一线治疗。2024年欧洲肿瘤内科学会（ESMO）大会上公布了该试验的积极数据。结果显示：16名患者中有 ...